Pcsk9-Inhibitor Drug Class That Grew out of UTSW Research Becomes a Game-Changer for Patient
News Feb 26, 2016
A 59-year-old heart patient with dangerously high levels of cholesterol that could not be adequately reduced by statin drugs now has near-normal cholesterol levels, thanks to a new class of drugs that grew out of work done by UT Southwestern Medical Center researchers. Two of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.
“If you take the core patients who are at highest risk, it makes you appreciate how important this drug class is,” said Dr. Amit Khera, Director of the Preventive Cardiology Program and Associate Professor of Internal Medicine at UT Southwestern. Frank Brown of Dallas, grandfather of six and the owner of Frank’s Wrecker Service in Dallas, has familial hypercholesterolemia, an inherited condition that causes high levels of cholesterol, especially low-density lipoprotein (LDL) cholesterol or “bad cholesterol.” High levels of LDL cholesterol are strongly associated with heart disease.
Mr. Brown, with a history of two heart attacks, had been aggressively treated with multiple drugs to reduce his cholesterol levels, but they remained stubbornly high.“When I first met Mr. Brown, he had a strong family history of heart disease, he had a cholesterol level that was ridiculously high with an LDL of 384, and he was having chest pains,” said Dr. Amit Khera, who is Mr. Brown’s cardiologist.
Dr. Khera, who holds the Dallas Heart Ball Chair in Hypertension and Heart Disease at UT Southwestern, was treating Mr. Brown with three cholesterol-lowering medications: a statin, which is a class of drugs that works by blocking a substance the body needs to make cholesterol; ezetimibe, a drug that blocks absorption of cholesterol in the intestine; and colesevelam, which sequesters bile acids. Even with this trio of medicines, Mr. Brown’s LDL cholesterol level hovered around 200.
The two PCSK9 inhibitors approved by the FDA last year were developed as a result of research done by UT Southwestern geneticists Dr. Helen Hobbs and Dr. Jonathan Cohen. Using data from the Dallas Heart Study, a population-based study that gathered extensive medical data on 6,000 Dallas residents, the two researchers showed that certain mutations to the gene that codes for the protein PCSK9 lead to low levels of cholesterol in the blood.
Further, Dr. Hobbs and Dr. Cohen found a woman who had inherited not one, but two of these mutations in the PCSK9 gene – one mutation from each parent. This woman had stunningly low levels of LDL cholesterol. While anything below 100 is considered good, her LDL cholesterol level was just 14. Crucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.
Their research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections. Dr. Hobbs, Director of the Eugene McDermott Center for Human Growth and Development, holds the Eugene McDermott Distinguished Chair for the Study of Human Growth and Development, the Philip O’Bryan Montgomery, Jr., M.D. Distinguished Chair in Developmental Biology, and the 1995 Dallas Heart Ball Chair in Cardiology Research. Dr. Cohen, Professor of Internal Medicine and with the McDermott Center, holds the C. Vincent Prothro Distinguished Chair in Human Nutrition Research.
Mr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.“In the world of cholesterol patients, most are well-controlled with statins, and they should stay on those,” said Dr. Khera. “But Mr. Brown is the perfect patient for PCSK9 inhibitors. We knew he could tolerate it because he’d been in a clinical trial, he knew how to administer the injections, and he was very high-risk. We’d exhausted the other options in trying to control his cholesterol.”
Two months after he started his biweekly injections of the new drug, Mr. Brown’s LDL cholesterol level was down to 111 – not quite normal, which is 100 or less – but an almost 50 percent reduction from the level it had been for years. It’s a good sign for Mr. Brown, who looks forward to many more years of running his business, watching Dallas Cowboys games, and spending time with his grandchildren.
“There are many more Frank Browns out there – patients who can’t control their cholesterol with the standard drugs,” said Dr. Khera. “It’s wonderful to have this option to offer this special set of patients.”
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE
Catalyst Biosciences Announces Positive Top-Line Data for Potential Hemophilia B TreatmentNews
All individuals with severe hemophilia improved to mild hemophilia activity levels after only six daily doses with a continuous linear increase in Factor IX clotting activity. These results suggest that long-term dosing of SQ CB 2679d has the potential to maintain stable clotting activity in the high-mild hemophilia to normal range.READ MORE
Cannabinoids Are Easier on the Brain Than Booze, Study FindsNews
The research was published in the journal Addiction.READ MORE